Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

vTv Therapeutics (VTVT) Accumulated Depreciation (2016 - 2021)

vTv Therapeutics' Accumulated Depreciation history spans 7 years, with the latest figure at $216000.0 for Q4 2020.

  • For Q4 2020, Accumulated Depreciation rose 45.95% year-over-year to $216000.0; the TTM value through Dec 2020 reached $216000.0, up 45.95%, while the annual FY2020 figure was $216000.0, 45.95% up from the prior year.
  • Accumulated Depreciation for Q4 2020 was $216000.0 at vTv Therapeutics, up from $148000.0 in the prior quarter.
  • Across five years, Accumulated Depreciation topped out at $10.5 million in Q4 2016 and bottomed at $148000.0 in Q4 2019.
  • The 5-year median for Accumulated Depreciation is $8.4 million (2018), against an average of $5.7 million.
  • The largest annual shift saw Accumulated Depreciation plummeted 98.24% in 2019 before it soared 45.95% in 2020.
  • A 5-year view of Accumulated Depreciation shows it stood at $10.5 million in 2016, then decreased by 12.8% to $9.1 million in 2017, then fell by 7.51% to $8.4 million in 2018, then tumbled by 98.24% to $148000.0 in 2019, then surged by 45.95% to $216000.0 in 2020.
  • Per Business Quant, the three most recent readings for VTVT's Accumulated Depreciation are $216000.0 (Q4 2020), $148000.0 (Q4 2019), and $8.4 million (Q4 2018).